Last update June 23, 2022
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
10-{3-[4-(2-Hydroxyethyl)piperidino]propyl}-NN-dimethylphenothiazine-2-sulphonamide; 2-{4-[3-(2-Dimethylsulphamoylphenothiazin-10-yl)propyl]piperazin-1-yl}ethanol is Pipotiazine in Chemical name.
Is written in other languages:10-{3-[4-(2-Hydroxyethyl)piperidino]propyl}-NN-dimethylphenothiazine-2-sulphonamide; 2-{4-[3-(2-Dimethylsulphamoylphenothiazin-10-yl)propyl]piperazin-1-yl}ethanol is also known as
10-{3-[4-(2-Hydroxyethyl)piperidino]propyl}-NN-dimethylphenothiazine-2-sulphonamide; 2-{4-[3-(2-Dimethylsulphamoylphenothiazin-10-yl)propyl]piperazin-1-yl}ethanol belongs to these groups or families:
Main tradenames from several countries containing 10-{3-[4-(2-Hydroxyethyl)piperidino]propyl}-NN-dimethylphenothiazine-2-sulphonamide; 2-{4-[3-(2-Dimethylsulphamoylphenothiazin-10-yl)propyl]piperazin-1-yl}ethanol in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Typical, first generation antipsychotic. Prochlorperazine is a phenothiazine derivative with general properties similar to those of chlorpromazine. It has been used in the treatment of schizophrenia and other psychoses. Oral or intramuscular administration (depot).
Since the last update we have not found published data on its excretion in breastmilk.
Product with very few bibliographic references, without known pharmacokinetic data and marketed in few countries.
Known safer alternatives are preferable (Parikh 2014), especially during the neonatal period and in the event of prematurity.
It has been withdrawn from the market in many countries. (Mustafa 2017)
See below the information of this related product: